Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tiagabine hydrochloride
Drug ID BADD_D02211
Description Tiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor.
Indications and Usage For the treatment of partial seizures
Marketing Status approved; investigational
ATC Code N03AG06
DrugBank ID DB00906
KEGG ID D02097
MeSH ID D000078308
PubChem ID 91274
TTD Drug ID D0ED7U
NDC Product Code 63459-416; 63459-412; 82019-0004; 16714-151; 0093-5031; 0093-8072; 63459-404; 72205-086; 16714-153; 29902-0004; 62756-224; 72205-085; 16714-152; 16714-154; 63459-402; 69766-061; 0093-8076; 72205-084; 0093-5030; 62756-200; 72205-087
UNII DQH6T6D8OY
Synonyms Tiagabine | N-(4,4-di(3-Methylthien-2-yl)but-3-enyl)nipecotic acid | Gabitril | NO 329 | NO-329 | Tiagabine Hydrochloride | (R)-(4,4-bis(3-Methyl-2-thienyl)-3-butenyl)-3-piperidinecarboxylic acid, Hydrochloride | Tiagabine, (S)-isomer | NO 328 | NO-328
Chemical Information
Molecular Formula C20H26ClNO2S2
CAS Registry Number 145821-59-6
SMILES CC1=C(SC=C1)C(=CCCN2CCCC(C2)C(=O)O)C3=C(C=CS3)C.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Skin ulcer23.07.03.003; 24.04.03.007--
Smear cervix abnormal13.20.02.001---
Somnolence17.02.04.006; 19.02.05.003--
Speech disorder17.02.08.003; 19.19.02.002; 22.12.03.027---
Stomatitis07.05.06.005--
Stupor17.02.04.007; 19.02.05.004---
Sudden death02.03.04.013; 08.04.01.003--
Suicide attempt19.12.01.004--
Syncope02.11.04.015; 17.02.04.008; 24.06.02.012--
Tachycardia02.03.02.007---
Tendinous contracture15.07.01.001---
Thirst08.01.09.021; 14.03.02.007---
Thrombocytopenia01.08.01.002---
Thrombophlebitis24.01.02.001---
Tinnitus04.04.01.002; 17.04.07.004--
Tooth abscess07.09.01.003; 11.01.04.003---
Tremor17.01.06.002--
Urethritis11.01.14.008; 20.07.02.001--
Urinary incontinence17.05.01.008; 20.02.02.010--
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria10.01.06.001; 23.04.02.001--
Vaginal haemorrhage21.08.01.001; 24.07.03.005--
Vaginal infection11.01.10.002; 21.14.02.002--
Vasodilatation23.06.05.006; 24.03.02.003---
Vertigo04.04.01.003; 17.02.12.002--
Visual field defect06.02.07.003; 17.17.01.001---
Visual impairment06.02.10.013---
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
The 7th Page    First    Pre   7 8    Next   Last    Total 8 Pages